Selventa

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

October 29, 2003

Former Incyte, Proteome Executive Joins Mechanism Discovery Company

Wednesday October 29, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biotechnology company that develops conceptual biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of Sharan A. Pagano as Vice President, Business Development & Alliances.

AVEO Pharmaceuticals, Inc.

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

November 17, 2003

CAMBRIDGE, Mass. - November 17, 2003 - GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year collaborative agreement with Merck & Co., Inc. (NYSE: MRK). Under the agreement, GenPath will use its proprietary cancer models to identify essential tumor maintenance genes which maybe suitable targets for the development of small molecule oncology agents. GenPath will also use its inducible, spontaneous tumor models to guide candidate drug selection and optimization.

Morphotek, Inc.

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

December 15, 2003

Exton, PA, December 15, 2003 -- Morphotek Inc. announced today that the United States Patent and Trademark Office has issued it U.S. Patent 6,656,736 covering the generation of novel, genetically evolved yeast strains for use in biotherapeutic and biological product discovery, development, and manufacturing.

Affinnova, Inc.

Aéropostale Selects Affinnova's IDEA™ Technology To Evolve Winning Product Designs and Merchandising Mix With Direct Consumer Insight

Aéropostale Selects Affinnova's IDEA™ Technology To Evolve Winning Product Designs and Merchandising Mix With Direct Consumer Insight

December 15, 2003

First apparel retailer joins growing number of leading consumer products companies using Affinnova's IDEA™ technology to optimize the product development and marketing cycle

Mascoma Corporation

Mascoma Acquires SunOpta BioProcess Inc.

Mascoma Acquires SunOpta BioProcess Inc.

September 1, 2010

Creates global biofuels leader and industry’s first comprehensive capability for low-cost cellulosic biofuels

CGI Pharmaceuticals, Inc.

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

Gilead Sciences to Acquire CGI Pharmaceuticals for up to $120 Million

June 25, 2010

Deal to Broaden Gilead's Research Expertise into Kinase Biology and Chemistry

Ensemble Therapeutics Corporation

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

August 24, 2010

Progress with Macrocyclic-Based Drug Discovery Platform Highlighted

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society (ACS) National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

Poster Presentations:

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

Flagship's David Berry Quoted in article in Technology Review: Death Knell for Some Clean Tech Companies

August 18, 2010

Partner David Berry, associated with several of Flagship's companies in the Sustainability sector. He was recently interviewed for a TR article on the potentials for a carbon cap-and-trade system in the US.

 

Carbon Design Systems

RTL models fly at KHz speeds

RTL models fly at KHz speeds

January 5, 2004

By Clive Maxfield
EEdesign.com
January 05, 2004 (8:56 PM EST)

Morphotek, Inc.

Morphotek announces research and development agreement with the National Cancer Institute for the development of antibodies for the treatment of pancratic, ovarian and lung cancer

Morphotek announces research and development agreement with the National Cancer Institute for the development of antibodies for the treatment of pancratic, ovarian and lung cancer

January 12, 2004

Exton, PA, January 12, 2004 - Morphotek® Inc. announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by researchers at the NCI. Morphotek will apply its proprietary MORPHODOMA® antibody technology to the development of novel antibodies for use in the treatment of pancreatic, ovarian and lung cancers.